| Issue Date | Title | Author(s) | Source | WOS | Fulltext/Archive link |
| 2016 | Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors | Spinner, M. A.; Vina, M. F.; Elder, L.; Arai, S.; Johnston, L.; Meyer, E.; Miklos, D.; Muffly, L.; Negrin, R. S.; Shizuru, J.; Wen-Kai Weng ; Laport, G. G.; Strober, S.; Lowsky, R.; Rezvani, A. R. | Blood | | |
| 2015 | Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms | Narayan, R.; Benjamin, J.; Laport, G.; Tian, L.; Tate, K.; Elder, L.; Galvez, L.; Armstrong, R.; Sheehan, K.; Lowsky, R.; Arai, S.; Johnston, L.; Miklos, D.; Muffly, L. S.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Strober, S.; Negrin, R.; Meyer, E. | Blood | | |
| 2018 | Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation | Muffly, L.; Sheehan, K.; Armstrong, R.; Jensen, K.; Tate, K.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood Advances | | |
| 2016 | Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin | Nakasone, H.; Miklos, D. B.; Meyer, E.; Rezvani, A.; Muffly, L.; Wen-Kai Weng ; Arai, S.; Johnston, L.; Laport, G. G.; Shizuru, J. A.; Negrin, R.; Strober, S.; Lowsky, R. | Biology of Blood and Marrow Transplantation | | |
| 2016 | Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma | Neppalli, A. K.; Shizuru, J.; Johnston, L. J.; Muffly, L. S.; Wen-Kai Weng ; Negrin, R.; Meyer, E.; Laport, G.; Lowsky, R.; Arai, S.; Miklos, D. B.; Rezvani, A. R. | Journal of Clinical Oncology | | |
| 2020 | Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma | Wen-Kai Weng ; Arai, S.; Rezvani, A.; Johnston, L.; Lowsky, R.; Miklos, D.; Shizuru, J.; Muffly, L.; Meyer, E.; Negrin, R. S.; Wang, E.; Almazan, T.; Million, L.; Khodadoust, M.; Li, S. F.; Hoppe, R. T.; Kim, Y. H. | Blood Advances | | |
| 2014 | Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience | Wudhikarn, K.; Lavori, P.; Arai, S.; Johnston, L.; Laport, G. G.; Lowsky, R.; Miklos, D. B.; Shizuru, J. A.; Hoppe, R. T.; Benjamin, J.; Meyer, E.; Negrin, R.; Wen-Kai Weng | Biology of Blood and Marrow Transplantation | | |
| - | Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma | Lemieux, C.; Muffly, L. S.; Rezvani, A.; Lowsky, R.; Iberri, D. J.; Craig, J. K.; Frank, M. J.; Johnston, L. J.; Liedtke, M.; Negrin, R.; Wen-Kai Weng ; Meyer, E.; Shizuru, J.; Shiraz, P.; Arai, S.; Miklos, D. B.; Sidana, S. | Bone Marrow Transplantation | | |
| 2016 | Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation | Muffly, L. S.; Sheehan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood | | |
| 2015 | Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis | Chu, M. P.; Brody, J.; Kohrt, H. E.; Frank, M. J.; Khodadoust, M.; Reddy, S.; Advani, R. H.; Gupta, N. K.; Laport, G.; Maeda, L. S.; Meyer, E.; Miklos, D. B.; Negrin, R.; Rezvani, A. R.; Wen-Kai Weng ; Sheehan, K.; Faham, M.; Czerwinski, D. K.; Okada, A.; Levy, R. | Blood | | |
| 2018 | Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells | Meyer, E.; Laport, G. G.; Tantsura, I.; Tang, S. W.; Sahaf, B.; Rangarajan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Sheehan, K.; Arai, S.; Johnston, L.; Muffly, L.; Lowsky, R.; Rezvani, A.; Wen-Kai Weng ; Miklos, D.; Negrin, R. S. | Biology of Blood and Marrow Transplantation | | |
| 2016 | Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation | Veeraputhiran, M.; Arai, S.; Lowsky, R.; Miklos, D. B.; Meyer, E.; Muffly, L. S.; Negrin, R.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Johnston, L. J. | Journal of Clinical Oncology | | |
| 2017 | Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation | Veeraputhiran, M.; Yang, L. Y.; Sundaram, V.; Arai, S.; Lowsky, R.; Miklos, D.; Meyer, E.; Muffly, L.; Negrin, R.; Rezvani, A.; Shizuru, J.; Wen-Kai Weng ; Johnston, L. | Biology of Blood and Marrow Transplantation | | |
